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Endovascular repair of infrarenal abdominal aortic
aneurysms (AAAs) is an attractive approach in the
treatment of patients with infrarenal AAAs. The evalu-
ation, to date, of the early and midterm results suggest
a significant decrease in hospital stay and periproce-
dural morbidity when compared with open surgical
repair.1,2 Initial results with this approach have been
promising, and the follow-up to date suggests that it
will become an integral part of the armamentarium in
the treatment of patients with aneurysmal disease.
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Purpose: Contemporary treatment of abdominal aortic aneurysms (AAA) includes trans-
abdominal (TA), retroperitoneal (RP), and endovascular (EV) repair. This study com-
pares the cost and early (30-day) results of a consecutive series of AAA repair by means
of these three methods in a single institution.
Methods: A total of 125 consecutive AAA repairs between February 1993 and August
1997 were reviewed. Risk factors, 30-day morbidity and mortality rates, and hospital
stay and cost were analyzed according to method of repair (TA, RP, EV). Cost was nor-
malized by means of a conversion factor to maintain confidentiality. Cost analysis
includes conversion to TA repair (intent to treat) in the EV group.
Results: One hundred twenty-five AAA repairs were performed with the TA (n = 40), RP
(n = 24), or EV (n = 61) approach. Risk factors among the groups (age, coronary artery
disease, hypertension, diabetes, chronic obstructive pulmonary disease, and cigarette
smoking) were not statistically different, and thus the groups were comparable.
The average estimated blood loss was significantly lower for EV (300 mL) than for RP
(700 mL) and TA (786 mL; P > .05). Statistically significant higher cost for TA and RP
for pharmacy and clinical laboratories (likely related to increased length of stay [LOS])
and significantly higher cost for EV in supplies and radiology (significantly reducing
cost savings in LOS) were revealed by means of an itemized cost analysis. Operating
room cost was similar for EV, TA, and RP. There were six perigraft leaks (9.6%) and six
conversions to TA (9.6%) in the EV group.
Conclusion: There were no statistically significant differences in mortality rates among
TA, RP, and EV. Respiratory failure was significantly more common after TA repair,
compared with RP or EV, whereas wound complications were more common after RP.
Overall cost was significantly higher for TA repair, with no significant difference in
cost between EV and RP. EV repair significantly shortened hospital stay and intensive
care unit (ICU) use and had a lower morbidity rate. Cost savings in LOS were signif-
icantly reduced in the EV group by the increased cost of supplies and radiology,
accounting for a similar cost between EV and RP. Considering the increased resource
use preoperatively and during follow-up for EV patients, the difference in cost
between TA and EV may be insignificant. EV repair is unlikely to save money for the
health care system; its use is likely to be driven by patient and physician preference, in
view of a significant decrease in the morbidity rate and length of hospital stay. (J Vasc
Surg 1999;30:59-67.)
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Retroperitoneal repair of infrarenal AAAs has
been preferred by some physicians because of a per-
ceived decrease in pulmonary complications and
faster return of gastrointestinal function.3-4 When
retroperitoneal repair is evaluated in a prospective
randomized fashion, compared with the transperi-
toneal approach, no advantage has been found by
some investigators,5 whereas others reported fewer
complications, shorter hospital stays, and lower costs
for the retroperitoneal approach.6 Nevertheless, the
retroperitoneal approach to infrarenal AAA repair has
slowly gained popularity and has become part of the
current acceptable approaches to aortic aneurysms.
Transperitoneal AAA repair is the standard
method used by most vascular surgeons in the treat-
ment of patients with infrarenal AAAs. Vascular sur-
geons are familiar with this technique, which has
been proven both safe and durable, with mortality
rates of approximately 2% to 4% and acceptable mor-
bidity rates less than 20%.7-9 In fact, the transperi-
toneal approach serves as the “gold standard” to
which other methods must be compared.
The availability of the endovascular approach at
the UCLA Medical Center has given us the unique
opportunity to evaluate the contemporary manage-
ment of infrarenal AAAs, comparing the endovascu-
lar, retroperitoneal, and transperitoneal approaches
in a consecutive series of patients seen between
February 1993 and August 1997. This study com-
pares the cost and early (30-day) results in a consec-
utive series of AAAs that were repaired by means of
one of these three methods in a single institution.
MATERIALS AND METHODS
All patients evaluated for endovascular repair of
infrarenal AAAs at the UCLA Medical Center between
February 1993 and August 1997 were included in this
review. Excluded from consideration were patients
who required additional procedures at the time of
aneurysm repair, such as visceral (renal, mesenteric)
bypass grafting procedures, peripheral bypass grafting
procedures, juxtarenal aneurysms requiring suprarenal
aortic clamping, or combined operations (ie, cholecys-
tectomy or carotid endarterectomy). In addition,
patients who did not meet physiologic inclusion 
criteria for endovascular repair (Food and Drug
Administration protocol, American Anesthesia Associ-
ation class I to IV, life expectancy longer than 2 years),
or had exclusion criteria (ruptured aneurysm, active
infection, weight of more than 350 pounds, transplant
patients, bleeding diathesis, or aneurysm etiology
other than atherosclerosis) were also excluded from
consideration. Thus, only patients who were accept-
able candidates for surgical intervention were consid-
ered for endovascular repair. The patients were divid-
ed into three groups, according to the method of
repair: transabdominal (TA), retroperitoneal (RP), or
endovascular (EV). Risk factors, 30-day morbidity and
mortality rates, length of hospital stay, and costs were
analyzed according to the method of repair.
Medical records were retrospectively reviewed, and
risk factors were noted (age, coronary artery disease,
hypertension, diabetes mellitus, chronic obstructive
pulmonary disease, and history of cigarette smoking).
Each group was compared for preoperative risk factors
to determine any statistical difference. Morphologic
features of the aneurysm that excluded the patient as a
candidate for EV repair, and thus proceeding with con-
ventional (TA, RP) surgical intervention, were noted.
During the study period, all patients were con-
sidered for EV repair of their infrarenal AAA.
Patients who were not deemed candidates for EV
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Mortality Morbidity
Hospital stay/ Cost
P > .3 Respiratory failure Wound Other* ICU (days) factor
TA 
(n = 40) 2.5% (1) 12.5% (5) 2.5% (1) 15% (6) 9.6/3.1 1469.8
(P < .05) (P < .05)
RP 
(n = 24) 4.2% (1) 4.2% (1) 12.5% (3) 12.5% (3) 8.1/3.1 1176.3†
(P < .05)
EV 
(n = 61) 0 0 0 13.1% (8) 4/0.5 1000‡
P < .0001
Overall 1.6% (2) 4.8% 3.2% 13.6% 7.2/2.2
(n = 125)
*Pneumonia, bleeding, myocardial infarction, renal failure, graft thrombosis (no statistical significance).
†RP vs. TA, P < .05.
‡EV vs. TA, P < .0003; EV vs. RP, P > .1.
repair because of morphologic reasons were then
considered for surgical intervention. The most com-
mon anatomic reason for exclusion in the EV group
was the absence of a proximal neck, with presence of
significant iliac aneurysmal disease, occlusive disease,
or both preventing adequate EV access being the
second and third most frequent causes for exclusion.
Operative factors were also analyzed. These
included total operating time, total blood loss, and
any intraoperative complications requiring a change
in operative plan. This included conversions to sur-
gical repair in the EV group or additional proce-
dures required in the surgical group.
Postoperative morbidity occurring within the first
30 days or before hospital discharge were noted. These
included pneumonia, postoperative bleeding, myocar-
dial infarction, renal failure, graft thrombosis, respira-
tory failure, and wound complications. Mortality was
defined as death occurring within 30 days of the pro-
cedure or during the same hospital admission. 
The length of hospital stay was analyzed and
included any preoperative days that were necessary
as part of the workup for the AAA. Days in the
intensive care unit were analyzed separately and were
included in the hospital stay.
Total cost of the procedure and hospital stay
were analyzed. This included the costs of the entire
hospital stay and procedure, which were further ana-
lyzed specifically as to operating room costs, sup-
plies, pharmacy, radiology, respiratory service, and
clinical laboratories. The cost of the EV device was
included in supplies. Cost figures were normalized
with a conversion factor to maintain institutional
confidentiality. The conversion factor was deter-
mined to be a denominator that would yield a cost
factor of 1000 in the group with the lowest total
cost. All other cost factors were determined by this
denominator. Hospital charges or reimbursement
were not considered. Patients who were initially
treated with the EV approach but converted to a
transperitoneal approach were included in the total
cost of the EV group. Total cost for all groups
includes the entire hospitalization, including costs
related to complications. 
Surgical technique in the TA group included
either a midline or a bilateral subcostal incision. All
RP exposures were carried out by making a curvilin-
ear incision, starting at the tip of the 11th rib, and
continuing obliquely to a point midway between the
pubis and the umbilicus. Graft configurations were
either tube or bifurcated, depending on the presence
or absence of aneurysmal disease at the iliac arteries.
All grafts were made of Dacron.
All patients in the EV group were examined pre-
operatively with imaging modalities to determine
precise aneurysm and aortic measurements. A pre-
operative arteriogram was routine in the examina-
tion of EV patients and was selectively used in the
surgical groups. All preoperative evaluation was
excluded from cost consideration to avoid the bias
that would otherwise occur, because EV group
patients were all part of a strict Food and Drug
Administration protocol. Most patients were
referred to our institution, with studies done at
other facilities. Cost information of these studies was
not available. Furthermore, if these initial studies
suggested appropriate anatomy for EV repair, they
frequently were repeated for more detail (computed
tomography with 3 mm slices). Magnetic resonance
imaging and magnetic resonance angiography were
performed most frequently in the EV group. Thus,
to avoid bias against the EV group, all preoperative
evaluations were excluded from cost considerations. 
The EV procedure was carried through a trans-
femoral approach, either unilateral or bilateral,
depending on the graft configuration (tube versus
bifurcated versus aortoiliac with femorofemoral
bypass graft). The grafts were manufactured by
EndoVascular Technologies (Menlo Park, Calif) and
consisted of a Dacron material with attachment sys-
tems proximally and distally.
RESULTS
A total of 125 patients with AAAs underwent
either open or EV repairs at the UCLA Medical
Center between February 1993 and August 1997.
The TA approach was used in 40 patients, the RP
approach in 24, and the EV approach in 61. Risk
factors among the three groups are presented in
Table I. There was a statistically significant higher
number of patients with hyperlipidemia in the RP
group. Otherwise, there was no statistically signifi-
cant difference in preoperative risk factors among
the groups, and thus, the groups were comparable.
Anatomic differences between the EV and surgical
group dictated method of repair. Otherwise, the
groups were comparable.
The 30-day mortality rate was 2.5% (1 of 40) in
the TA group, 4.2% (1 of 24) in the RP group, and
no mortality occurred in the EV group (0 of 61).
There was no statistically significant difference in
mortality rates among the three groups (P > .3).
The death in the transabdominal group was
caused by a myocardial infarction in a patient with
respiratory failure. The mortality in the retroperi-
toneal group was caused by multisystem organ fail-
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ure after a peripheral embolization during aneurysm
repair. This patient had had a stroke 2 months
before surgery during a coronary catheterization.
He had an expanding AAA. 
The 30-day morbidity rate is summarized in
Table II. There was no statistically significant differ-
ence in the incidence of pneumonia, perioperative
bleeding, myocardial infarction, renal failure, or
graft thrombosis among the three groups. There
were no instances of major peripheral embolization
in the EV group. A statistically significant increased
incidence of respiratory failure was noted in the TA
group. Respiratory failure requiring reintubation
with prolonged respiratory support developed in five
of the 40 patients operated on via the TA approach,
versus one patient in the RP group, and no patients
in the EV group (P < .05). Wound complications
were more frequent in the RP group, with three
patients in whom either wound dehiscence (one
patient) or superficial wound infection requiring
partial opening of the incision (two patients) devel-
oped, compared with one patient in the TA
approach and no patients in the EV group in whom
a small wound collection developed (TA versus RP
versus EV, P < .05). The single wound dehiscence
(partial) in the RP group occurred in a morbidly
obese patient (weighing 340 lb), who had chronic
obstructive pulmonary disease and was successfully
treated conservatively. A significantly higher inci-
dence of arrhythmias was seen in the TA and RP
group compared with the EV group. All other com-
plications occurred with a similar incidence among
the three groups.
As mentioned before, anatomic differences dic-
tated EV or open surgical repair. Of the 61 EV cases,
30 were tube grafts, 20 were bifurcated prosthesis,
and there were seven patients treated with an aor-
touniiliac and femorofemoral bypass grafting proce-
dure. In the TA group, there were 16 aortoaortic
(tube) graft repairs and 24 bifurcated prosthetic
graft implantations. Of the 24 retroperitoneal
repairs, there were 10 tube and 14 bifurcated grafts.
Thus, aortoaortic repairs were most common in the
EV group, likely reflecting the initial availability of
that particular prosthesis.
The operating time was similar for the three
groups. Mean operating room times were 283 ± 92
minutes for the EV group, 296 ± 115 for the RP
group, and 298 ± 122 for the TA group. The mean
operating time in the EV group was similar for the
tube (231 minutes) and the bifurcated (246 min-
utes) configurations. However, tube graft repairs
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Table I. Preoperative risk factors in patients with abdominal aortic aneurysm
Endovascular Retroperitoneal Transabdominal
Number of patients 61 24 40
Hypertension 55% (30) 58% (14) 58% (23)
Coronary artery disease 38% (21) 38% (9) 43% (17)
Smoking history 53% (29) 46% (11) 53% (21)
COPD 22% (12) 25% (6) 23% (9)
Diabetes mellitus 9% (5) 13% (3) 8% (4)
Peripheral vascular disease 9% (5) 13% (3) 20% (8)
Earlier stroke 11% (6) 4% (1) 20% (8)
Hyperlipidemia 9% (5) 21% (5) 8% (3)
P < .001; COPD, chronic obstructive pulmonary disease.
Table II. Postoperative morbidity in 125 patients with abdominal aortic aneurysm
Complication Endovascular (n = 61) Retroperitoneal (n = 24) Transabdominal (n = 40) P value
Blood loss 300 mL 700 mL 786 mL < .05
Arrhythmias 0 12.5% (3) 10% (4) < .05
Pneumonia 0 0 2.5% (1) NS
Respiratory failure 0 4.2% (1) 12.5% (5) < .05
Postoperative bleeding 0 0 2.5% (1) NS
Wound 0 12.5% (3) 2.5% (1) < .05
Myocardial infarction 0 4.2% (1) 2.5% (1) NS
Renal failure 0 4.2% (1) 2.5% (1) NS
Graft limb thrombosis or stenosis 3.6% (2) 0 5% (2) NS
Endoleak 9.8% (6) NA NA
were most common early in the EV experience. The
mean operative time for aortouniiliac and femoro-
femoral repair was significantly longer (372 minutes)
than EV tube or bifurcated repairs. The mean esti-
mated blood loss for the TA group was 786 mL
(range, 150 to 3000 mL). The RP group had a
mean blood loss of 700 mL (range, 200 to 3000
mL). The difference between these two groups was
not significant. The EV group had a significantly
lower estimated blood loss, with a mean of 300 mL
(range, 100 to 1300 mL; P < .05).
The total length of hospital stay was significantly
lower in the EV group, which had a mean hospital
stay (± SD) of 4 ± 2.5 days, compared with 9.6 ± 4.0
days for the TA group and 8.1 ± 3.1 for the retroperi-
toneal group (P < .0001). A similar significant
decrease in ICU length of stay was noted, with the
EV group having a mean ICU day stay of 0.5 ± 1.3
days, compared with 3.1 ± 2.1 days for the TA group
and 3.1 ± 1.6 days for the RP group (P < .0001).
Overall results for the entire experience, combin-
ing the three groups, yields a mortality rate of 1.6% (2
of 125 patients) and an overall morbidity rate of
21.6%, which included all postoperative complications.
The overall mean length of hospital stay for the entire
series was 7.2 days, with an ICU stay of 2.2 days. 
In the EV group, there were six perigraft leaks
persistent at 30 days (9.6%). There were also six con-
versions to surgical repair in the EV group (9.6%).
All conversions were done at the time of attempted
EV repair. Three conversions were necessary because
of difficulty with access caused by small or tortuous
iliac vessels, two were necessary because of signifi-
cant endoleaks at the distal attachment site of a tube
graft repair, and one was necessary because of subin-
timal placement of the proximal attachment system
early in the experience. All patients in the EV group
undergoing conversion to surgical repair recovered
without complications and are included within the
EV group as an intent-to-treat analysis.
The overall cost factor for the EV group was
1000. This was statistically lower than the cost factor
for the TA group, which was 1469.8 (P < .05). The
cost factor for the RP group was 1176.3, which is not
significantly different statistically from the cost factor
for the EV group. A statistically significant higher cost
for pharmacy and clinical laboratories for the TA and
RP groups was revealed by means of further itemized
cost analysis; this was likely related to the increased
length of stay. A significantly higher cost factor in sup-
plies and radiology, which significantly reduced the
cost savings obtained because of a decrease in length
of stay, was seen in the EV group. Operating room
costs were similar for the EV, the TA, and the RP
groups. There were no differences in the cost factor
between tube and bifurcated repair within the EV,
TA, or RP groups. However, within the EV group,
aortouniiliac/femorofemoral repairs had a significant-
ly higher cost factor (1604), compared with the over-
all cost factor for the entire group. One of the seven
patients within the aortouniiliac/femorofemoral
group had a prolonged hospital stay (15 days) because
of complications; however, even when this prolonged
stay was eliminated from the cost analysis, the cost
factor for the remaining six patients in this group was
significantly higher (1328). This was probably caused
by an increase in operating time, because the length
of hospital stay was similar (mean, 3.6 days) to the
overall EV group. Cost factor analysis is presented in
Table III.
DISCUSSION
Contemporary management of infrarenal AAA is
likely to be expanded to include EV repair. Recent
initial reports of the EV experience with infrarenal
AAAs have suggested a decrease in morbidity rate
and length of hospital stay. Although mortality rates
have not been significantly different, some series
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Table III. Cost analysis of 125 patients with abdominal aortic aneurysm
Item Endovascular (n = 61) Retroperitoneal (n = 24) Transabdominal (n = 40) P value
Operating room 289.4 289.8 323.6 NS
Supplies 348.6 240.6 264.1 < .05
Respiratory service 21.6 110.8 162.1 < .05
Pharmacy 143.7 326.9 377.1 < .05
Radiology 203 63 57.9 < .05
Clinical laboratories 58.4 131.9 214.6 < .05
Total* 1000 ± 480.1† 1176 ± 466.3‡ 1469 ± 689.8 (See footnote)
*Cost factor ± SD
†Endovascular vs. transabdominal, P < .0003; endovascular vs. retroperitoneal, P > .1
‡Retroperitoneal vs. transabdominal, P < .05
have included patients with greater comorbidities,
which some investigators suggest may have eliminat-
ed any potential difference in mortality rates.
Nevertheless, it has been proposed that, because of
the significant decrease in length of stay, significant
cost savings should be realized.
Our experience to date suggests that patients
undergoing EV aneurysm repair do indeed have a sig-
nificantly shorter hospital stay. This is likely related to
the rapid recovery that is seen after EV repair and a
significant decrease in the morbidity rate that is specif-
ically related to respiratory failure. The mortality rate
in our series was not significantly different among the
TA, RP, and EV approaches. However, the failure to
demonstrate a difference in a relatively small series
must be interpreted with caution. Nevertheless, series
reported to date concur with our findings; mortality
does not seem to be significantly different between
the EV and the surgical approaches.1-2 This under-
scores the excellent results that can be accomplished
with modern surgical techniques, even in patients
with significant comorbidities.
The RP approach has been preferred by some
physicians because of a perceived faster recovery
time and less impact on pulmonary function.
Randomized trials to date have had mixed results. In
a study by Cambria et al,5 no significant advantage
was demonstrated for the RP approach. Sicard and
colleagues,6 on the other hand, showed not only a
decrease in postoperative complications, but also a
decrease in length of hospital stay and lower cost,
when compared with the TA approach. In our expe-
rience, we saw a decrease of 1.5 days in total hospi-
tal stay in the RP group, which translated into a sig-
nificant decrease in cost compared with the TA
approach. No significant difference in cost was seen
when comparing the RP approach with the EV
approach. A significantly lower incidence of respira-
tory failure was seen in the RP group, compared
with the TA group. However, a significantly
increased incidence of wound complications was
seen with the RP approach. This, however, did not
prolong the length of hospital stay or lead to any
serious sequelae.
Our overall results must be interpreted with cau-
tion. First, it is a relatively small series, which, when
further subdivided into three groups, dilutes the sta-
tistical power of its conclusions and may not demon-
strate differences, even though they may exist (Type
II statistical error). In spite of this, significant differ-
ences were noted, particularly in the early cost of
care between the TA group and EV group and the
overall morbidity rates between the surgical group
and the EV group. Second, although there were no
significant differences in comorbidities among the
groups, there were anatomic differences between the
surgical group and the EV group. We attempted to
decrease the impact of these differences by eliminat-
ing complex repairs beyond standard infrarenal
repair with tube or bifurcated grafts from considera-
tion. Nevertheless, because this was not a random-
ized prospective study, potential error in the com-
parison is inevitably introduced.
Third, although performance of the TA approach
was distributed among our colleagues, the RP
approach was performed mostly by one surgeon.
Although this may introduce bias in the results, no
differences were noted in the results of the TA group
among our team, suggesting comparability in surgi-
cal skill. Fourth, the EV group represents the experi-
ence with one particular device (Endovascular
Technologies/Guidant, Menlo Park, Calif), which
may or may not be comparable with other devices
under investigation.
Finally, this series only looks at the initial results
and cost. Preoperative evaluation was not included.
We believe that, because the minimum necessary
studies for EV repair remains to be established, it
would be unfair to include these at this time. The
eventual long-term outcome and cost of care of
patients in the EV group remains more important.
This must await further analysis, which is currently
in progress.
Considering the increased resource use that will
be required, at least within the next 10 years, in
patients treated with the EV approach, the potential
cost savings related to the length of hospital stay
may be eliminated. In fact, we could not demon-
strate a significant difference between the cost of the
EV approach and the RP approach, in spite of a 4-
day difference in the length of hospital stay. Most of
the savings were eliminated because of the cost of
supplies, radiology equipment, and personnel neces-
sary for EV grafting.
In conclusion, transperitoneal repair is associated
with a higher incidence of respiratory failure and
overall cost when compared with the RP approach
or the EV approach. EV AAA repair significantly
shortens hospital stay and ICU use and has a lower
morbidity rate. Cost savings in the length of stay for
the EV group are significantly reduced by the
increased cost of supplies and radiology, which
accounts for the similar cost between EV repair and
RP repair. Considering the increased resource use
during follow-up for patients undergoing EV
aneurysm repair, the difference in cost between the
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TA approach and the EV approach may be insignifi-
cant. EV AAA repair is unlikely to save money for
the health care system; its use is likely to be driven
by patient and physician preference, because of a sig-
nificant decrease in morbidity rate and length of
hospital stay.
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Dr Jerry Goldstone (San Francisco, Calif). The objec-
tive of this study was to compare the cost and early results
of a consecutive series of abdominal aortic aneurysms
repaired by three methods: transfemoral endovascular,
transperitoneal open surgical, and retroperitoneal open sur-
gical. A total of 125 consecutive patients were treated in a
54-month interval. By means of simple math, this repre-
sents 2.3 aneurysm repairs per month or 28 per year.
Because the authors were the first physicians in this country
to implant a Guident-EVT endograft and because that pro-
cedure was performed in February 1993, I assume that this
report encompasses the entire UCLA experience with the
endovascular treatment of abdominal aortic aneurysms.
This leads me to my first set of questions. How many of the
endografts were tubes? How many were bifurcated? And
how many were aortouniiliac with femorofemoral bypass
grafts? Were there any differences in any of the variables,
such as procedure duration, blood loss, graft limb throm-
bosis or stenosis, or other complications, studied within
these groups? The authors acknowledge that these patients
were participants in a strictly monitored, Food and Drug
Administration-approved protocol. Were there any compas-
sionate-use patients in this study cohort, and, if so, how did
their results compare with that of the others? And what
about the learning curve? The UCLA group has now had a
large experience, perhaps the largest, with these particular
devices. Were there any differences in outcome measures
between the first part of the series and the last part? One
would anticipate that there would be differences.
How were the open surgical patients selected for
either retroperitoneal or transabdominal approaches? Was
there a protocol for this? If it was based on individual sur-
geon preference, could there have been patient-related
factors that influenced the decision and thereby influenced
the results? Were the retroperitoneal procedures per-
formed by one or two surgeons experienced with this
method, or was there also a learning curve here?
There was a statistically significant increased incidence
of respiratory failure in the transabdominal group. How
was respiratory failure defined for this study, and were
there any unusual features in this group of patients that
could have predisposed them to this postoperative com-
plication? For example, some of the transabdominal group
received a bilateral subcostal incision. This is, in my opin-
ion, a very unusual incision for an infrarenal aortic
aneurysm operation, in distinction from the supraumbili-
cal transverse incision popularized by the group at the
University of Michigan.
In contrast to respiratory complications, wound com-
plications were more frequent in the retroperitoneal
group. The authors didn’t mention the occurrence of a
flank bulge or hernia, which is a well-recognized and
bothersome complication after this approach. Were there
any such late wound problems?
Finally, about cost, one of the primary questions that
this study sought to answer: Do the figures presented rep-
resent actual cost, or do they represent charges? We all
know that these are not the same, although purely for
comparison purposes either one might be valid. Two of
the most significant costs for these treatments are the
length of hospital stay and the operating room costs.
The 9.6-day average hospitalization for the transab-
dominal group seems high by today’s standards. Many
series now report hospital discharge between 5 and 7 days
DISCUSSION
after uncomplicated abdominal aortic aneurysm repair. In
spite of the reduction in length of stay to 8.1 days in the
retroperitoneal group, this figure also seems excessively
long. In the recently reported EVT phase II trial, the aver-
age length of stay in the open surgery group was 7.1 days.
Were there any trends noted in the length of stay during
this 4.5-year interval, and what accounts for the seeming-
ly excessive hospitalizations? The length of stay averaged 4
days for the endovascular group; this period is essentially
identical to the 3.7 days in the EVT trial. The average time
for the procedures in this series ranged from 283 minutes
for endoluminal repair to 298 minutes for retroperitoneal
open repair. Again, these values appear to be long when
compared with the EVT phase II data; endovascular repair
averaged 168 and 212 minutes for the tube and bifurcat-
ed devices, respectively, and 174 minutes for open repair—
differences of at least 1 hour in each group. These are
expensive differences.
Another point worth mentioning is that the authors
excluded the cost of the preoperative imaging studies in
the endoluminal treatment group. Because these imaging
studies are essential to the safe conduction of the proce-
dure, I believe that their cost must be included in any eco-
nomic analysis. Furthermore, because of the uncertainties
about endoleaks, a certain number of postprocedure imag-
ing studies are performed in these patients, and although
they may be protocol driven, it is probable that at least
some of them will be performed in the absence of proto-
col requirements. Therefore, I believe that these charges
also must be included in the endovascular tally. 
I have one last question about cost. What was the cost
of the endograft device, was it included in the analysis, and
if not, why not? 
In summary, the UCLA group has demonstrated that
they can treat abdominal aortic aneurysms in at least three
ways with equally excellent results. However, I believe that
they have underestimated the resource use required for
endovascular repair, and, therefore, I question the conclu-
sion that transabdominal repair is more expensive than
endoluminal repair. This report does not define the future
role of endovascular aortic aneurysm repair, but that was
not its purpose. It does, however, add to the growing body
of knowledge about this exciting treatment modality.
Dr William J. Quiñones-Baldrich. I would like to
thank D. Goldstone for his comments and excellent ques-
tions. I will try to answer these questions in order.
There were 61 patients in the endovascular group.
Thirty of these patients had tube endografts, there were
24 bifurcated endovascular grafts, and seven patients
underwent aortouniiliac and femorofemoral reconstruc-
tion. Dr Goldstone raised the issue about the overall time
in the operating room for these cases, which appears
somewhat longer than what has been reported in the ini-
tial EVT report. The average time for endovascular repair
was 283 minutes. When this is broken down into the tube,
bifurcated, and aortouniiliac implants, the tube grafts had
an average time of 231 minutes, versus 246 minutes for
the bifurcated grafts, which is not a significant difference.
However, aortouniiliac reconstructions with femoro-
femoral bypass grafts had a significantly longer operative
time, 372 minutes, which helps explain why our overall
average time is higher than has been previously reported.
In addition, surgical time in our operating room starts as
soon as the patient receives anesthesia; during general
anesthesia, this is as soon as the endotracheal tube has
been placed. Therefore, the time that it takes to place the
Foley catheter, prepare the patient, etc, is included in the
operative time. Other complications within these groups,
however, were not significantly different. There was one
patient who received a tube graft on a compassionate-use
basis. This patient recovered well from his surgery; how-
ever, he died of respiratory failure 8 months later.
There is clearly a learning curve with the endovascular
grafts. However, if we look at our own series, it is evident
that easier cases were selected in the early part of the expe-
rience, whereas now we’re tackling more difficult cases. So,
although the learning curve is there, we are not seeing any
significant impact on the early and late part of our experi-
ence. We have seen, however, a significant increase in oper-
ative time in the aortouniiliac-femorofemoral reconstruc-
tion. Therefore, I do not believe that the “learning curve”
would affect our conclusions.
Patients in the surgical group were selected on the
basis that they were not candidates for endovascular grafts.
In deciding whether to proceed in a transabdominal or a
retroperitoneal approach, there is no protocol at our insti-
tution for selection. This is based on the surgeon’s prefer-
ence. Most of the retroperitoneal cases were my own,
because I favor that approach for the surgical repair of
most infrarenal abdominal aortic aneurysms. Cases using
the transabdominal approach was distributed among our
group. As far as patient-related factors to account for any
difference, there were certainly no differences in preoper-
ative risk factors, with the exception of hyperlipidemia,
which I do not believe would significantly affect early out-
come. Certainly for the retroperitoneal approach, there is
a learning curve; however, this learning curve did not
occur during this study period, because I have been doing
retroperitoneal abdominal aortic aneurysm surgery almost
routinely since 1989.
Respiratory failure was defined as a patient requiring
reintubation for more than 72 hours after initial extubation.
Most patients with respiratory failure had a significant his-
tory of chronic obstructive pulmonary disease. Regarding
the transverse abdominal incision: This is the preference of
one of the surgeons in our group. As far as the bulging or
hernia that can occur with the retroperitoneal approach, this
certainly was something that I saw early on in my experi-
ence. However, for the last 6 years, it has been my practice
to divide the internal oblique muscle along the rectus bor-
der, which seems to have eliminated this problem.
This report deals only with costs, not charges. These
costs were obtained from the confidential computerized sys-
tem that is used in a hospital to track these items. Thus, the
figures all represent costs. Regarding trends in hospital stay:
I do not have this information at hand; however, it is my
JOURNAL OF VASCULAR SURGERY
66 Quiñones-Baldrich et al July 1999
impression that there has been a decrease in length of hos-
pital stay, particularly for the transabdominal and retroperi-
toneal group. We have all been forced to reduce the length
of these stays because of the current environment.
However, the hospital stays reported include prolonged
stays for complications. In addition, an earlier presentation
noted that a low mortality rate actually can be reflected in a
longer hospital stay, and vice versa. However, the hospital
stay for the transabdominal approach was significantly
longer than that for the retroperitoneal approach, about 1.5
days longer.
The cost of preoperative evaluation was not included
in the calculation of costs, mainly because I felt this
would establish a bias against the endovascular group.
This particular group of patients is currently under pro-
tocol, and therefore there are several studies (particular-
ly magnetic resonance angiography and magnetic reso-
nance imaging) that would significantly increase the cost
without really giving us actual information on the cost of
the procedures and the hospital stay. In addition, the
preoperative evaluation for surgical repair varies among
our group. Some physicians are more liberal with
angiography than others, and, again, this would intro-
duce variables into the mix that would make interpreta-
tion of the data more difficult. Furthermore, many of
these studies are done outside our facility, and, therefore,
we have no cost information on them. Often patients
who come to or are referred to our institution already
have had a computed tomography scan. 
One of the conclusions that we have proposed specu-
lates on the very fact that you mentioned about the cost of
postoperative studies in patients that have endoleaks. This
certainly will be a significant factor. However, keep in
mind that this particular study only looks at the first 30
days of care. Again, I felt that going beyond that not only
would be difficult because of the uncertainty involved in
the particular studies that are necessary to elucidate an
endoleak, but also because the endovascular patients are
part of a protocol.
The cost of the endograft is certainly an important fac-
tor in increasing the cost of the endovascular repair. I
don’t have an exact figure on the cost of the endograft;
however, my information is that it is somewhere between
$5000 and $6000.
Finally, I agree with you that the cost of the transab-
dominal approach may not be significantly higher than the
endovascular approach, because of the cost of surveillance
in these patients, and this is exactly the reason why we
concluded that endovascular repair is unlikely to decrease
the overall cost to the health care system. This is most evi-
dent because the initial cost for the first 30 days of care is
not that much different, in spite of a significant difference
between the surgical and endovascular groups for the
length of hospital stay and morbidity rate.
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